Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4.

Science advances

Jain P, Dvorkin-Gheva A, Mollen E, Malbeteau L, Xie M, Jessa F, Dhavarasa P, Chung S, Brown KR, Jang GH, Vora P, Notta F, Moffat J, Hedley D, Boutros PC, Wouters BG, Koritzinsky M.
PMID: 33962950
Sci Adv. 2021 May 07;7(19). doi: 10.1126/sciadv.abf7114. Print 2021 May.

There is an urgent need to identify vulnerabilities in pancreatic ductal adenocarcinoma (PDAC). PDAC cells acquire metabolic changes that augment NADPH production and cytosolic redox homeostasis. Here, we show that high NADPH levels drive activity of NADPH oxidase 4...

Cite
Jain P, Dvorkin-Gheva A, Mollen E, et al. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Sci Adv. 2021;7(19)doi: 10.1126/sciadv.abf7114.
Jain, P., Dvorkin-Gheva, A., Mollen, E., Malbeteau, L., Xie, M., Jessa, F., Dhavarasa, P., Chung, S., Brown, K. R., Jang, G. H., Vora, P., Notta, F., Moffat, J., Hedley, D., Boutros, P. C., Wouters, B. G., & Koritzinsky, M. (2021). NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Science advances, 7(19), . https://doi.org/10.1126/sciadv.abf7114
Jain, Pallavi, et al. "NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4." Science advances vol. 7,19 (2021). doi: https://doi.org/10.1126/sciadv.abf7114
Jain P, Dvorkin-Gheva A, Mollen E, Malbeteau L, Xie M, Jessa F, Dhavarasa P, Chung S, Brown KR, Jang GH, Vora P, Notta F, Moffat J, Hedley D, Boutros PC, Wouters BG, Koritzinsky M. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Sci Adv. 2021 May 07;7(19). doi: 10.1126/sciadv.abf7114. Print 2021 May. PMID: 33962950; PMCID: PMC8104867.
Copy Download .nbib Format: NLM
Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency.

Oncoimmunology

Yoo SM, Lau VWC, Aarts C, Bojovic B, Steinberg G, Hammill JA, Dvorkin-Gheva A, Ghosh R, Bramson JL.
PMID: 34777917
Oncoimmunology. 2021 Nov 09;10(1):1995168. doi: 10.1080/2162402X.2021.1995168. eCollection 2021.

Engineered T cell therapies have revolutionized modern oncology, however processes for manufacturing T cell therapies vary and the impact of manufacturing processes On the cell product is poorly understood. Herein, we have used a commercially available hollow fiber membrane...

Cite
Yoo SM, Lau VWC, Aarts C, et al. Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology. 2021;10(1):1995168doi: 10.1080/2162402X.2021.1995168.
Yoo, S. M., Lau, V. W. C., Aarts, C., Bojovic, B., Steinberg, G., Hammill, J. A., Dvorkin-Gheva, A., Ghosh, R., & Bramson, J. L. (2021). Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology, 10(1), 1995168. https://doi.org/10.1080/2162402X.2021.1995168
Yoo, Seung Mi, et al. "Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency." Oncoimmunology vol. 10,1 (2021): 1995168. doi: https://doi.org/10.1080/2162402X.2021.1995168
Yoo SM, Lau VWC, Aarts C, Bojovic B, Steinberg G, Hammill JA, Dvorkin-Gheva A, Ghosh R, Bramson JL. Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology. 2021 Nov 09;10(1):1995168. doi: 10.1080/2162402X.2021.1995168. eCollection 2021. PMID: 34777917; PMCID: PMC8583081.
Copy Download .nbib Format: NLM
Increased Monocyte-Derived CD11b.

Frontiers in immunology

Cass SP, Mekhael O, Thayaparan D, McGrath JJC, Revill SD, Fantauzzi MF, Wang P, Reihani A, Hayat AI, Stevenson CS, Dvorkin-Gheva A, Botelho FM, Stämpfli MR, Ask K.
PMID: 34603325
Front Immunol. 2021 Sep 16;12:740330. doi: 10.3389/fimmu.2021.740330. eCollection 2021.

RATIONALE: The accumulation of macrophages in the airways and the pulmonary interstitium is a hallmark of cigarette smoke-associated inflammation. Notably, pulmonary macrophages are not a homogenous population but consist of several subpopulations. To date, the manner in which cigarette...

Cite
Cass SP, Mekhael O, Thayaparan D, et al. Increased Monocyte-Derived CD11b. Front Immunol. 2021;12:740330doi: 10.3389/fimmu.2021.740330.
Cass, S. P., Mekhael, O., Thayaparan, D., McGrath, J. J. C., Revill, S. D., Fantauzzi, M. F., Wang, P., Reihani, A., Hayat, A. I., Stevenson, C. S., Dvorkin-Gheva, A., Botelho, F. M., Stämpfli, M. R., & Ask, K. (2021). Increased Monocyte-Derived CD11b. Frontiers in immunology, 12740330. https://doi.org/10.3389/fimmu.2021.740330
Cass, Steven P, et al. "Increased Monocyte-Derived CD11b." Frontiers in immunology vol. 12 (2021): 740330. doi: https://doi.org/10.3389/fimmu.2021.740330
Cass SP, Mekhael O, Thayaparan D, McGrath JJC, Revill SD, Fantauzzi MF, Wang P, Reihani A, Hayat AI, Stevenson CS, Dvorkin-Gheva A, Botelho FM, Stämpfli MR, Ask K. Increased Monocyte-Derived CD11b. Front Immunol. 2021 Sep 16;12:740330. doi: 10.3389/fimmu.2021.740330. eCollection 2021. PMID: 34603325; PMCID: PMC8481926.
Copy Download .nbib Format: NLM
Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection.

iScience

Hare DN, Baid K, Dvorkin-Gheva A, Mossman KL.
PMID: 33319181
iScience. 2020 Nov 27;23(12):101864. doi: 10.1016/j.isci.2020.101864. eCollection 2020 Dec 18.

Type 1 interferon (IFN) plays a critical role in early antiviral defense and priming of adaptive immunity by signaling upregulation of host antiviral IFN-stimulated genes (ISGs). Certain stimuli trigger strong activation of IFN regulatory factor 3 (IRF3) and direct...

Cite
Hare DN, Baid K, Dvorkin-Gheva A, et al. Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection. iScience. 2020;23(12):101864doi: 10.1016/j.isci.2020.101864.
Hare, D. N., Baid, K., Dvorkin-Gheva, A., & Mossman, K. L. (2020). Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection. iScience, 23(12), 101864. https://doi.org/10.1016/j.isci.2020.101864
Hare, David N, et al. "Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection." iScience vol. 23,12 (2020): 101864. doi: https://doi.org/10.1016/j.isci.2020.101864
Hare DN, Baid K, Dvorkin-Gheva A, Mossman KL. Virus-Intrinsic Differences and Heterogeneous IRF3 Activation Influence IFN-Independent Antiviral Protection. iScience. 2020 Nov 27;23(12):101864. doi: 10.1016/j.isci.2020.101864. eCollection 2020 Dec 18. PMID: 33319181; PMCID: PMC7726339.
Copy Download .nbib Format: NLM
Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?.

Chest

Naiel S, Tat V, Padwal M, Vierhout M, Mekhael O, Yousof T, Ayoub A, Abed S, Dvorkin-Gheva A, Ask K.
PMID: 31778676
Chest. 2020 May;157(5):1207-1220. doi: 10.1016/j.chest.2019.11.009. Epub 2019 Nov 26.

Chronic lung disease accounts for a significant global burden with respect to death, disability, and health-care costs. Due to the heterogeneous nature and limited treatment options for these diseases, it is imperative that the cellular and molecular mechanisms underlying...

Cite
Naiel S, Tat V, Padwal M, et al. Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest. 2019;157(5):1207-1220doi: 10.1016/j.chest.2019.11.009.
Naiel, S., Tat, V., Padwal, M., Vierhout, M., Mekhael, O., Yousof, T., Ayoub, A., Abed, S., Dvorkin-Gheva, A., & Ask, K. (2020). Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest, 157(5), 1207-1220. https://doi.org/10.1016/j.chest.2019.11.009
Naiel, Safaa, et al. "Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?." Chest vol. 157,5 (2020): 1207-1220. doi: https://doi.org/10.1016/j.chest.2019.11.009
Naiel S, Tat V, Padwal M, Vierhout M, Mekhael O, Yousof T, Ayoub A, Abed S, Dvorkin-Gheva A, Ask K. Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease: Will Cell-Specific Targeting Be the Key to the Cure?. Chest. 2020 May;157(5):1207-1220. doi: 10.1016/j.chest.2019.11.009. Epub 2019 Nov 26. PMID: 31778676.
Copy Download .nbib Format: NLM
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity.

Molecular therapy oncolytics

Hammill JA, Kwiecien JM, Dvorkin-Gheva A, Lau VWC, Baker C, Wu Y, Bezverbnaya K, Aarts C, Heslen CW, Denisova GF, Derocher H, Milne K, Nelson BH, Bramson JL.
PMID: 32368616
Mol Ther Oncolytics. 2020 Apr 14;17:278-292. doi: 10.1016/j.omto.2020.04.001. eCollection 2020 Jun 26.

Tumor-targeted chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR-T cells) have demonstrated striking clinical success, but their use has been associated with a constellation of toxicities. A better understanding of the pathogenesis of these toxicities is required to improve the...

Cite
Hammill JA, Kwiecien JM, Dvorkin-Gheva A, et al. A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Mol Ther Oncolytics. 2020;17:278-292doi: 10.1016/j.omto.2020.04.001.
Hammill, J. A., Kwiecien, J. M., Dvorkin-Gheva, A., Lau, V. W. C., Baker, C., Wu, Y., Bezverbnaya, K., Aarts, C., Heslen, C. W., Denisova, G. F., Derocher, H., Milne, K., Nelson, B. H., & Bramson, J. L. (2020). A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Molecular therapy oncolytics, 17278-292. https://doi.org/10.1016/j.omto.2020.04.001
Hammill, Joanne A, et al. "A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity." Molecular therapy oncolytics vol. 17 (2020): 278-292. doi: https://doi.org/10.1016/j.omto.2020.04.001
Hammill JA, Kwiecien JM, Dvorkin-Gheva A, Lau VWC, Baker C, Wu Y, Bezverbnaya K, Aarts C, Heslen CW, Denisova GF, Derocher H, Milne K, Nelson BH, Bramson JL. A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Mol Ther Oncolytics. 2020 Apr 14;17:278-292. doi: 10.1016/j.omto.2020.04.001. eCollection 2020 Jun 26. PMID: 32368616; PMCID: PMC7191649.
Copy Download .nbib Format: NLM
Total particulate matter concentration skews cigarette smoke's gene expression profile.

ERJ open research

Dvorkin-Gheva A, Vanderstocken G, Yildirim AÖ, Brandsma CA, Obeidat M, Bossé Y, Hassell JA, Stampfli MR.
PMID: 27995131
ERJ Open Res. 2016 Nov 09;2(4). doi: 10.1183/23120541.00029-2016. eCollection 2016 Oct.

Exposure of small animals to cigarette smoke is widely used as a model to study the pathogenesis of chronic obstructive pulmonary disease. However, protocols and exposure systems utilised vary substantially and it is unclear how these different systems compare....

Cite
Dvorkin-Gheva A, Vanderstocken G, Yildirim AÖ, et al. Total particulate matter concentration skews cigarette smoke's gene expression profile. ERJ Open Res. 2016;2(4)doi: 10.1183/23120541.00029-2016.
Dvorkin-Gheva, A., Vanderstocken, G., Yildirim, A. �. �., Brandsma, C. A., Obeidat, M., Bossé, Y., Hassell, J. A., & Stampfli, M. R. (2016). Total particulate matter concentration skews cigarette smoke's gene expression profile. ERJ open research, 2(4), . https://doi.org/10.1183/23120541.00029-2016
Dvorkin-Gheva, Anna, et al. "Total particulate matter concentration skews cigarette smoke's gene expression profile." ERJ open research vol. 2,4 (2016). doi: https://doi.org/10.1183/23120541.00029-2016
Dvorkin-Gheva A, Vanderstocken G, Yildirim AÖ, Brandsma CA, Obeidat M, Bossé Y, Hassell JA, Stampfli MR. Total particulate matter concentration skews cigarette smoke's gene expression profile. ERJ Open Res. 2016 Nov 09;2(4). doi: 10.1183/23120541.00029-2016. eCollection 2016 Oct. PMID: 27995131; PMCID: PMC5165723.
Copy Download .nbib Format: NLM
Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society

Vierhout M, Ayoub A, Naiel S, Yazdanshenas P, Revill SD, Reihani A, Dvorkin-Gheva A, Shi W, Ask K.
PMID: 34107123
Wound Repair Regen. 2021 Jul;29(4):548-562. doi: 10.1111/wrr.12946. Epub 2021 Jun 09.

Since the discovery of the myofibroblast over 50 years ago, much has been learned about its role in wound healing and fibrosis. Its origin, however, remains controversial, with a number of progenitor cells being proposed. Macrophage-myofibroblast transition (MMT) is...

Cite
Vierhout M, Ayoub A, Naiel S, et al. Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence. Wound Repair Regen. 2021;29(4):548-562doi: 10.1111/wrr.12946.
Vierhout, M., Ayoub, A., Naiel, S., Yazdanshenas, P., Revill, S. D., Reihani, A., Dvorkin-Gheva, A., Shi, W., & Ask, K. (2021). Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 29(4), 548-562. https://doi.org/10.1111/wrr.12946
Vierhout, Megan, et al. "Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence." Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society vol. 29,4 (2021): 548-562. doi: https://doi.org/10.1111/wrr.12946
Vierhout M, Ayoub A, Naiel S, Yazdanshenas P, Revill SD, Reihani A, Dvorkin-Gheva A, Shi W, Ask K. Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence. Wound Repair Regen. 2021 Jul;29(4):548-562. doi: 10.1111/wrr.12946. Epub 2021 Jun 09. PMID: 34107123.
Copy Download .nbib Format: NLM
Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency.

Oncoimmunology

Yoo SM, Lau VWC, Aarts C, Bojovic B, Steinberg G, Hammill JA, Dvorkin-Gheva A, Ghosh R, Bramson JL.
PMID: 34777917
Oncoimmunology. 2021 Nov 09;10(1):1995168. doi: 10.1080/2162402X.2021.1995168. eCollection 2021.

Engineered T cell therapies have revolutionized modern oncology, however processes for manufacturing T cell therapies vary and the impact of manufacturing processes On the cell product is poorly understood. Herein, we have used a commercially available hollow fiber membrane...

Cite
Yoo SM, Lau VWC, Aarts C, et al. Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology. 2021;10(1):1995168doi: 10.1080/2162402X.2021.1995168.
Yoo, S. M., Lau, V. W. C., Aarts, C., Bojovic, B., Steinberg, G., Hammill, J. A., Dvorkin-Gheva, A., Ghosh, R., & Bramson, J. L. (2021). Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology, 10(1), 1995168. https://doi.org/10.1080/2162402X.2021.1995168
Yoo, Seung Mi, et al. "Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency." Oncoimmunology vol. 10,1 (2021): 1995168. doi: https://doi.org/10.1080/2162402X.2021.1995168
Yoo SM, Lau VWC, Aarts C, Bojovic B, Steinberg G, Hammill JA, Dvorkin-Gheva A, Ghosh R, Bramson JL. Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency. Oncoimmunology. 2021 Nov 09;10(1):1995168. doi: 10.1080/2162402X.2021.1995168. eCollection 2021. PMID: 34777917; PMCID: PMC8583081.
Copy Download .nbib Format: NLM
Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Oncoimmunology

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.
PMID: 29900060
Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.

Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile...

Cite
Atherton MJ, Stephenson KB, Tzelepis F, et al. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology. 2018;7(7):e1445459doi: 10.1080/2162402X.2018.1445459.
Atherton, M. J., Stephenson, K. B., Tzelepis, F., Bakhshinyan, D., Nikota, J. K., Son, H. H., Jirovec, A., Lefebvre, C., Dvorkin-Gheva, A., Ashkar, A. A., Wan, Y., Stojdl, D. F., Belanger, E. C., Breau, R. H., Bell, J. C., Saad, F., Singh, S. K., Diallo, J. S., & Lichty, B. D. (2018). Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology, 7(7), e1445459. https://doi.org/10.1080/2162402X.2018.1445459
Atherton, Matthew J, et al. "Transforming the prostatic tumor microenvironment with oncolytic virotherapy." Oncoimmunology vol. 7,7 (2018): e1445459. doi: https://doi.org/10.1080/2162402X.2018.1445459
Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018. PMID: 29900060; PMCID: PMC5993491.
Copy Download .nbib Format: NLM
Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.

JCI insight

Jeyanathan M, Fritz DK, Afkhami S, Aguirre E, Howie KJ, Zganiacz A, Dvorkin-Gheva A, Thompson MR, Silver R, Cusack RP, Lichty BD, O'Byrne PM, Kolb M, Medina MFC, Dolovich MB, Satia I, Gauvreau GM, Xing Z, Smaill F.
PMID: 34990408
JCI Insight. 2022 Jan 06; doi: 10.1172/jci.insight.155655. Epub 2022 Jan 06.

BACKGROUND: Adenoviral (Ad)-vectored vaccines are typically administered via intramuscular injection to humans, incapable of inducing respiratory mucosal immunity. However, aerosol delivery of Ad-vectored vaccines remains poorly characterized and its ability to induce mucosal immunity in humans is unknown. This...

Cite
Jeyanathan M, Fritz DK, Afkhami S, et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight. 2022;doi: 10.1172/jci.insight.155655.
Jeyanathan, M., Fritz, D. K., Afkhami, S., Aguirre, E., Howie, K. J., Zganiacz, A., Dvorkin-Gheva, A., Thompson, M. R., Silver, R., Cusack, R. P., Lichty, B. D., O'Byrne, P. M., Kolb, M., Medina, M. F. C., Dolovich, M. B., Satia, I., Gauvreau, G. M., Xing, Z., & Smaill, F. (2022). Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI insight, . https://doi.org/10.1172/jci.insight.155655
Jeyanathan, Mangalakumari, et al. "Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans." JCI insight vol. (2022). doi: https://doi.org/10.1172/jci.insight.155655
Jeyanathan M, Fritz DK, Afkhami S, Aguirre E, Howie KJ, Zganiacz A, Dvorkin-Gheva A, Thompson MR, Silver R, Cusack RP, Lichty BD, O'Byrne PM, Kolb M, Medina MFC, Dolovich MB, Satia I, Gauvreau GM, Xing Z, Smaill F. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight. 2022 Jan 06; doi: 10.1172/jci.insight.155655. Epub 2022 Jan 06. PMID: 34990408.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries